Abstract
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (NP-SIXO) currently in development for the treatment of hyperuricemia in patients with gout. Febuxostat was found not to reduce, but to potentiate the hERG channel mediated potassium currents. The agonist effect was voltage (only present at positive potentials) and use-dependent. Febuxostat has been shown to have no effect on cardiac INa and Ca currents at clinically relevant concentrations. This study evaluated the effect of febuxostat on cardiac action potentials (AP) in isolated canine Purkinje fibers, and to test whether febuxostat could blunt the effects of pharmacological agents that prolong the action potential duration (APD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
